Biologic activity of the novel small molecule STAT3 inhibitor LLL12 against canine osteosarcoma cell lines by Jason I Couto et al.
Couto et al. BMC Veterinary Research 2012, 8:244
http://www.biomedcentral.com/1746-6148/8/244RESEARCH ARTICLE Open AccessBiologic activity of the novel small molecule
STAT3 inhibitor LLL12 against canine
osteosarcoma cell lines
Jason I Couto1, Misty D Bear1, Jiayuh Lin2,3, Michael Pennel5, Samuel K Kulp6, William C Kisseberth4
and Cheryl A London1*Abstract
Background: STAT3 [1] has been shown to be dysregulated in nearly every major cancer, including osteosarcoma
(OS). Constitutive activation of STAT3, via aberrant phosphorylation, leads to proliferation, cell survival and resistance
to apoptosis. The present study sought to characterize the biologic activity of a novel allosteric STAT3 inhibitor,
LLL12, in canine OS cell lines.
Results: We evaluated the effects of LLL12 treatment on 4 canine OS cell lines and found that LLL12 inhibited
proliferation, induced apoptosis, reduced STAT3 phosphorylation, and decreased the expression of several
transcriptional targets of STAT3 in these cells. Lastly, LLL12 exhibited synergistic anti-proliferative activity with the
chemotherapeutic doxorubicin in the OS lines.
Conclusion: LLL12 exhibits biologic activity against canine OS cell lines through inhibition of STAT3 related cellular
functions supporting its potential use as a novel therapy for OS.
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The Signal Transducers and Activators of Transcription
(STATs) are a family of cell signaling proteins that play
critical roles in inflammation, proliferation and differen-
tiation [1-3]. The STAT family is comprised of 7 isoforms
with a variety of unique but also overlapping functions.
STAT proteins play critical roles in responding to extracel-
lular signals from growth factors and cytokines, as well as
regulating gene transcription in the nucleus. STAT3 in
particular has been shown to be dysregulated in many
cancers including osteosarcoma (OS) and is frequently
associated with malignant transformation and resistance
to apoptosis in other tumor types [4-6].
In the normal cell, activation of cell surface receptors
induces phosphorylation of specific tyrosine residues on
STAT3, either through activation of receptor tyrosine
kinase’s (RTKs) or janus kinases (JAKs), depending on* Correspondence: cheryl.london@cvm.osu.edu
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reproduction in any medium, provided the orthe nature of the signaling stimulus. The phosphorylated
STAT3 (pSTAT3) molecules then homodimerize via
their SH-2 domains and subsequently translocate into
the nucleus where binding to promoter elements of tar-
get genes acts to regulate their transcription [7,8]. While
STAT3 activation is transient in normal cells due to a
host of endogenous protein regulators (e.g., PIAS,
SOCS), neoplastic cells often display constitutive STAT3
activation, which contributes to increased angiogenesis,
metastasis and chemotherapy resistance [9,10].
Although originally discovered as a protein involved in
the pathway transducing a signal in response to inter-
feron [11], STAT3 was not linked to cancer until it was
shown to be essential for v-src mediated cellular trans-
formation [12]. The importance of STAT3 in tumor
progression and survival is supported by the fact that
overexpression of pSTAT3 has been linked to poor prog-
nosis in several cancers and as such, has been proposed
as a relevant target for therapeutic intervention [13-15].
Our work and that of others has demonstrated that
both human and canine OS cell lines and tumorstd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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represents a potential therapeutic target for this disease
[4,13,16]. The identification of novel therapeutic targets
for OS is critical given that approximately 40% of chil-
dren and over 90% of dogs will die from OS [17,18]. To
this end, several small molecule STAT3 inhibitors have
been developed and some have shown promising activity
both in vitro and in mouse xenograft models [19-21].
However, most of these inhibitors have suffered from
issues such as poor solubility that preclude their clinical
development. Using structure based design, we have
developed LLL12 as a non-peptide small molecule inhi-
bitor of STAT3 that possesses good solubility and predict-
able oral bioavailability [20]. LLL12 binds to the
phosphorylated tyrosine on STAT3 monomers, blocking
dimerization and subsequent translocation into the nu-
cleus, abrogating its function as a transcription factor. The
purpose of this study was to characterize the biologic ac-
tivity of this new STAT3 inhibitor, LLL12, in canine OS
cells and evaluate its ability to inhibit STAT3 and its
downstream targets.Methods
Cell lines and reagents
Canine OS cell lines OSA 8 and OSA 16 were provided by
Jaime Modiano (University of Minnesota, Minneapolis,
MN), the canine D17 OS cell line was purchased from
American Type Cell Culture Collection (ATCC, Manassas,
VA), and the canine Abrams OS cell line was provided by
Doug Thamm (Colorado State University, Fort Collins,
CO). OSA 8, OSA 16 and D17 were maintained in RPMI-
1640 supplemented with 10% FBS, non-essential amino
acids, sodium pyruvate, penicillin, streptomycin, L-
glutamine, and HEPES (4-(2-hydroxythyl)-1-piperazinee-
thanesulfonic acid) at 35°C, supplemented with 5% CO2.
The Abrams cell line was cultured in DMEM medium with
10% FBS and L-glutamine. Normal canine osteoblasts (Cell
Applications Inc, San Diego, CA) were cultured in canine
osteoblast medium (Cell Application Inc). LLL12 was
synthesized and purified as described previously [20]. The
following antibodies were used for Western blotting
experiments: pSTAT3 (Y705, Cell Signaling Technology,
Danvers, MA), total STAT3 (Cell Signaling Technology),
survivin (Novus Biologicals, Littleton, CO) and β-actin
(Santa Cruz Biotechnology, Santa Cruz, CA).
Cell proliferation
OS cells (2.5 × 103) were seeded in triplicate in 96-well
plates overnight in 10% FBS supplemented medium and
incubated with DMSO or increasing concentrations of
LLL12, doxorubicin, or both for 24 hours. The medium
was removed and the plates were frozen at −80°C over-
night before processing with the CyQUANTW CellProliferation Assay Kit (Molecular Probes, Eugene, OR)
according to the manufacturer’s instructions. Cell prolife-
ration was calculated as a percentage of the DMSO-
treated control wells and IC50 values derived after plotting
proliferation values on a logarithmic curve. Each experi-
ment was repeated 3 times.
Detection of apoptosis
OS cells (1.1×104) were seeded in triplicate in 96-well
plates overnight in 10% FBS supplemented medium and
incubated with medium only, DMSO or LLL12 at in-
creasing concentrations for 24 hours. Caspase 3/7 activ-
ity was determined using the SensoLyteW Homogeneous
AMC Caspase 3/7 Assay kit (Anaspec Inc, San Jose, CA)
according to manufacturer’s instructions. To further as-
sess apoptosis, 2×106 cells were plated in a T175 plate
and allowed to grow overnight before being treated with
DMSO or LLL12 (0.5 μM) for 24 hours. The cells were
then harvested and incubated with FITC conjugated
Annexin V and propidium iodide dye (PI) following the
manufacturer’s protocol (BD Biosciences, San Jose, CA)
before evaluation by flow cytometry (FACS Caliber, BD
Biosciences). CellQuest software (BD Biosciences) was
used to analyze the samples for early and late apoptosis.
Western blotting
OS cells or canine osteoblasts (2×106) in 1% FBS medium
were treated with DSMO or 0.5 μM LLL12 for 12 hours.
Normal canine osteoblasts were serum starved for 2 hours
prior to identical treatment. Protein lysates were prepared
and quantified, separated by SDS-PAGE, and Western blot-
ting was performed using previously described methods [4].
The membranes were incubated overnight with anti-
pSTAT3 (Y705, Cell Signaling Technology, Danvers, MA)
or anti-survivin (Novus Biologicals, Littleton, CO) anti-
bodies, then incubated with appropriate horseradish perox-
idase linked secondary antibodies, washed, and exposed to
substrate (SuperSignal West Dura Extended Duration
Substrate, Pierce, Rockford, IL). Blots were stripped,
washed, and reprobed for total STAT3 (Cell Signaling
Technology) or β-actin (Santa Cruz Biotechnology, Santa
Cruz, CA), respectively.
RT-PCR and qRT-PCR
Total RNA was extracted from canine OS cells in 10% FBS
supplemented medium following 12 hours of treatment
with DMSO or 0.5 μM LLL12 using RNeasy Mini Kits
(Qiagen, Valencia, CA) according to the manufacturer’s
instructions. After RNA extraction, samples were treated
with DNase I using RQ1 Rnase-Free DNase (Promega,
Madison, WI). cDNA was generated from 2 μg of total RNA
using Superscript III reverse transcriptase kit (Invitrogen,
Carlsbad, CA) according to the manufacturer’s instructions.
For each PCR reaction, 1/20 of the resultant cDNAwas used
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canine survivin, cyclin D1, BCL-2, VEGFA, MCL-1 and 18 s
are listed in Table 1, as are the annealing temperatures for
each reaction. Standard PCR was performed with all primer
sets and amplicon length verified through agarose gel elec-
trophoresis and visualization of products using the Alpha
Imager system (Alpha Innotech Corp, San Leandro, CA).
To quantitatively measure the effect of LLL12 treat-
ment on STAT3 downstream targets, total RNA was
collected as described above. Real-time quantitative PCR
was performed using Applied Biosystem’s StepOne Plus
Real-Time PCR system (Applied Biosystems, Foster City,
CA). Canine survivin, cyclin D1, BCL-2, VEGFA, MCL-1
and 18 s mRNA were detected using Fast SYBR green
PCR master mix (Applied Biosystems) according to the
manufacturer’s protocol. All reactions were performed in
triplicate and included non-template controls for each
gene. Relative expression was calculated using the com-
parative threshold cycle method [22]. Experiments were
repeated 3 times using samples in triplicate.Drug combination analysis
Experiments were performed in 96-well plates. OS cells
were seeded at a density of 2.5×104 cells per well in
RPMI medium containing 10% FCS. Stock solutions of
LLL12 and doxorubicin were generated and serial
dilutions (2-fold) for each compound were prepared,
with the concentration range from .0625X to 4X the
IC50 value of each drug. To assess potential synergistic
interactions, the treatment regimen involved simultan-
eous treatment of cells with LLL12 and doxorubicin for
24 hours, in addition to controls consisting of cells
treated with the individual compounds alone for 24
hours. All treatments were performed in triplicate wells.
Following drug treatment, the number of viable cells in
each well was determined using CyQUANTW as
described previously. Drug interactions were analyzedTable 1 Primers for canine reverse transcriptase
polymerase chain reactions
Primers Primer sequences Tm°
Canine Survivin F 50- GAA GGC TGG GAG CCA GAT GAT G -30 66.4
Canine Survivin R 50- CGC ACT TTC TTT GCG GTC TC -30 62.4
Canine Cyclin D1 F 50- GTC TGC GAG GAG CAG AAG T -30 62.3
Canine Cyclin D1 R 50- GAG GAA GTG CTC GAT GAA GT -30 60.6
Canine BCL-2 F 50- GAG CAG CCA CAA CCG GAG AGT C -30 68.3
Canine BCL-2 R 50- CGG ATC TTT ATT TCA CGA GGC AC -30 62.8
Canine MCL-1 F 50- CAA CCA CGA GAC AGC CTT CCA AG -30 62.6
Canine MCL-1 R 50- CAC TGA AAA CAT GGA CAA TCA C -30 58.9
Canine 18s F 50- AAA TCC TTT AAC GAG GAT CCA TT -30 57.4
Canine 18s R 50- AAT ATA CGC TAT TGG AGC TGG A -30 58.9using CompuSyn 3.0.1 (ComboSyn, Inc.,Paramus, NJ),
which is based on the median effect model of Chou and
Talalay [23].
Statistical analysis
All the values reported are mean ± SD. Delta CTs from
qRT-PCR were compared using two sample t-tests and
Holm’s method [24] was used to control type-I error
across tests of multiple genes. The Jonckhere-Terpstra
(JT) test [25,26] was used to test for a monotone trend
in cell proliferation and caspase activity with dose of
drug. If the JT test was insignificant, we performed the
Mack-Wolfe test [27] for a non-monotone, or umbrella,
dose–response. All analyses were performed using SAS
Version 9.2 (SAS Inc., Cary, NC). The Mack-Wolfe test
was performed using the MWUSPU and MWUSPK SAS
macros developed by Juneau [28].
Results
LLL12 Inhibits the proliferation of canine OS cell lines
Canine OS cell lines were treated with increasing
concentrations of LLL12 (0.05 μM- 5 μM) for 24 hours
and effects on cell proliferation were assessed. LLL12
significantly reduced cell proliferation at concentrations
as low as 0.1 μM with the calculated IC50 concentrations
in the nanomolar range (231–411 nM) for all cell lines
(Figure 1). Normal canine osteoblasts were compara-
tively resistant to the anti-proliferative effects of LLL12,
with an approximately 7-fold higher calculated IC50 of
1.780 μM (Figure 1).
LLL12 Promotes apoptosis of canine OS lines
To determine if LLL12 growth inhibition was mediated
via apoptosis, canine OS cell lines were treated with
DMSO or LLL12 for 24 hours, and caspase 3/7 activity
was measured. In all cell lines, caspase 3/7 activity was
increased at 24 hours post treatment with LLL12 at
concentrations of 0.4-0.8 μM (Figure 2A). OS cells were
also stained with Annexin V-FITC/PI and analyzed by
flow cytometry to assess the percentage of early and late
apoptotic cells in the population. After a 24 hour exposure
to 0.5 μM LLL12 there was an increase in the proportion
of early apoptotic (Annexin V positive, up to 22-fold in-
crease) and late apoptotic (Annexin V/PI positive, up to
13-fold increase) cells. This correlated with data generated
from the caspase assay (Figure 2B). Normal canine
osteoblasts were treated and analyzed by flow cytometry
as described above, and were far less sensitive to the apop-
tosis inducing effects of LLL12 (Figure 2C).
LLL12 Treatment decreases pSTAT3 and survivin
expression in canine OS lines
Canine OS cells and normal canine osteoblasts were
treated with DMSO, 0.1 μM LLL12 or 0.5 μM LLL12 for
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Figure 1 Effects of LLL12 on the proliferation of canine OS cell
lines and normal osteoblasts. Canine OS cell lines (Abrams, OSA 8,
OSA 16 and D17) and normal canine osteoblasts were treated with
vehicle or LLL12 for 24 hours. Proliferation was analyzed using the
CyQUANTW cell proliferation assay kit. Proliferation values are listed
as a percentage of DMSO control. Experiments were performed in
triplicate and repeated three times. For each cell line, there was a
significant decreasing trend in cell proliferation with dose of LLL12
(p < 0.001).
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ence of its effect on STAT3 phosphorylation and survivin
expression. Western blot analysis revealed pSTAT3 was
completely downregulated following treatment with
0.5 μM LLL12 for only 4 hours, with a concomitant
downregulation of survivin expression (Figure 3A). As
expected, these results were time- and dose-dependent.Importantly, normal canine osteoblasts treated identically
to their OS counterparts had significantly lower pSTAT3
expression and demonstrated no change in survivin
expression (Figure 3B) following 0.5 μM LLL12 treatment
at 12 hours.
LLL12 Treatment decreases STAT3-mediated gene
transcription
To assess the effects of LLL12 on transcriptional targets
of STAT3 the expression of cyclin D1, BCL-2, MCL-1
and survivin was assessed using quantitative RT-PCR.
Standard PCR was run with all primer sets and amplicon
length verified prior to quantitative analysis. Expression
of the STAT3 regulated genes evaluated was significantly
downregulated in all 4 OS cell lines after 12 hours of
treatment with 0.5 μM LLL12 when compared to DMSO
treated cells (Figure 4) supporting the notion that
inhibition of pSTAT3 by LLL12 affects its transcriptional
activity.
LLL12 Enhances the antiproliferative effects of
doxorubicin in canine OS cells
To assess whether inhibition of pSTAT3 would enhance
the biologic activity of chemotherapy in OS cell lines,
Abrams and OSA 16 cells were treated with LLL12
(0.016 μM-1 μM), doxorubicin (0.022 μM-1.4 μM) or
both drugs in combination over a range of doses
reflecting multiple concentrations of their respective
IC50 concentrations ranging from 0.0625× to 4×. Dose–
response curves and Combination Index (CI) graphs
were generated and analyzed using Compusyn software
(Figure 5). The CI values were <1 in 12/14 dose
combinations in both OS cell lines tested demonstrating
that LLL12 exhibits synergistic anti-proliferative effects
with doxorubicin in these lines. The dose reduction
index (DRI), which determines the magnitude of dose
reduction allowed for each drug when given in synergis-
tic combination, as compared with the concentration of
a single agent that is needed to achieve the same effect
was 2.63-3.91 for LLL12 and doxorubicin in the OS
lines. These data further support the notion that LLL12
and doxorubicin interact in a synergistic manner in OS
cell lines.
Discussion
Despite some advances in our understanding of the
underlying molecular biology of OS, treatment for this
disease has not changed significantly over the last 15
years in dogs or people [29]. Surgical resection and ag-
gressive chemotherapy protocols are effective, but have
failed to improve the 5-year overall survival rate past 60-
70% in humans [18]. Similarly, in dogs, limb amputation
followed by adjuvant chemotherapy with doxorubicin or


















































































































































Figure 2 Evaluation of canine OS cell lines for apoptosis following LLL12 treatment. Canine OS cell lines treated with vehicle or LLL12 for
24 h. Apoptosis was assessed by measuring activated caspases 3 and 7 (A) using the SensolyteW Homogeneous AMC Caspase-3/7 Assay kit.
Experiments were performed in quadruplicate and repeated three times. The same canine OS cell lines were treated under identical conditions as
above and stained with annexin V-FITC/PI and analyzed by flow cytometry (B). Normal canine osteoblasts were treated under identical conditions
and stained as above (C). There was a significant increasing trend in caspase activity for all lines except OSA 8 (p<0.01).
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[30]. Treatment with doxorubicin and platinum based
compounds, the current standards of care in the field, also
come with the potential for significant toxicities including
myelosuppression, gastrointestinal toxicity, cardiotoxicityand in humans including ototoxicity and secondary malig-
nancies [31]. This is particularly relevant for pediatric
patients in whom late toxicities can substantially affect
quality of life. Clearly, new drugs and new therapeutic
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Figure 3 Analysis pSTAT3, STAT3 and survivin in canine OS cell
lines following LLL12 treatment. Canine OS cell lines were treated
with DMSO or LLL12 for 4, 8 and 12 hours prior to collection.
Normal canine osteoblasts were treated with DMSO or LLL12 for 12
hours prior to collection. Protein lysates were generated and
separated by SDS-PAGE and Western blotting for pSTAT3, STAT3,
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BCL-2 
Figure 4 Evaluation of STAT3-related gene expression using
qRT-PCR after LLL12 treatment. Canine OS cell lines were treated
with DMSO or 0.5 μM LLL12 for 12 hours. RNA was collected and
qRT-PCR was performed for survivin, cyclin D1, BCL-2 and MCL-1
and 18 s. Experiments were performed in triplicate and repeated
three times. Delta CTs from qRT-PCR were compared using two
sample t-tests and Holm’s method was used to control type-I error
across tests of multiple genes (**p<0.02, *p<0.001).
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associated with the current standard of treatment.
Our laboratory previously characterized constitutive
STAT3 activation in primary canine OS tumor samples
and canine OS cell lines, and showed that direct
downregulation of STAT3 protein expression in OS lines
using siRNA induced loss of cell viability and apoptosis
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Figure 5 LLL12 synergizes with doxorubicin in canine OS cell lines. Proliferation curves and combination index graphs of canine
(Abrams and OSA 16) OS cell lines after 24 hours of treatment with LLL12, doxorubicin, or both. For each cell line and treatment (LLL12 alone,
DOXO alone, LLL12 + DOXO) there was a significant decreasing trend in cell proliferation with dose (*p < 0.001).
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both developed at OSU) also impacted OS cell viability
and induced cell death in all cell lines evaluated [4,19].
In concordance with our work, STAT3 dysregulation has
been demonstrated in OS in humans, where high levels
of STAT3 correlated with metastasis and lower rates of
overall survival [13,32]. Together, these data define
STAT3 as an important target for therapeutic interven-
tion in OS, particularly given the fact that STAT3 func-
tion is dispensable in many normal cells.
The mechanism(s) of persistent STAT3 phosphoryl-
ation remain to be elucidated in OS. Constitutive STAT3
activation does not appear to occur through direct mu-
tation in STAT3 as it does with other known oncogenes
[10]. However, there are a multitude of ligands (e.g. IL-6,
OSM, EGF, HGF, IGF) and kinases (RTKs, JAKs, SRC
family members) that initiate STAT3 activation and thus
there are many potential upstream drivers that could
contribute to the observed dysregulation [9]. In our
prior studies we identified OSM as a potential driver of
STAT3 phosphorylation in canine OS tumor cells and
found that inhibition of STAT3 signaling disrupted OSM
induced biologic activities [33]. It is also possible that a
loss of STAT3 regulatory mechanisms may play a role in
sustained STAT3 pathway signaling.
STAT3 may also play a critical role in chemoresistance
in a number of cancer types, including OS [34,35]. The
mechanisms through which this may occur are not well
understood, although available data suggests that
upregulation of the drug-resistance and anti-apoptoticSTAT3-regulated genes survivin, MCL-1 and MDR1
may play a part. Indeed, research has shown that P-gp,
the product of the MDR1 gene, can have its expression
mediated by STAT3 [36], providing a possible mechan-
ism for STAT3-mediated chemotherapy resistance.
Experimental evidence generated by our laboratory
and by others has clearly demonstrated that disruption
of STAT3 signaling inhibits the survival and proliferation
of OS cell lines and decreases the growth of OS in
mouse models of disease [19,37,38]. However, the chal-
lenge has been to develop a STAT3 inhibitor that has
good potential for future clinical application. LLL12 is
an optimized analog of LLL3, a novel small molecule
allosteric STAT3 inhibitor that has been shown to in-
hibit proliferation and induce apoptosis in various can-
cer cell lines in vitro and in several mouse xenograft
models, including OS [20,39,40]. LLL12 works by bind-
ing to STAT3 monomers at the phosphorylation site on
Y705 and thereby preventing STAT3 dimerization and
translocation into the nucleus. Similarly, anti-STAT3
therapies, such as dominant negative STAT3 molecules,
RNA interference and antisense oligonucleotides have
been shown to be effective against a number of tumor
types in vitro, but have yet to be tested in clinical trials,
due in part to drug delivery issues including cell perme-
ability, stability and solubility of the DNA, RNA and
small molecules. With respect to the small molecule
inhibitors previously tested in canine OS, FLLL32
suffered from lower activity than LLL12 and solubility
issues that precluded its further use in clinical trials and
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binding site of the STAT3 monomer, unlike its opti-
mized analog LLL12, which has a 10-fold increase in
simulated binding energies to STAT3 [40].
Our collaborator (J.Lin) has demonstrated that LLL12
has no off-target effects at concentrations used in this
work (less than 1 μM, data not shown), and does not in-
hibit any of the other STAT family members [41]. Our
current work shows that LLL12 inhibits cell viability while
inducing apoptosis in canine OS cell lines expressing
elevated levels of pSTAT3. LLL12 is quite potent, with
IC500s for the 4 canine OS lines between 0.23 μM and
0.41 μM. Importantly, the IC50 generated for normal ca-
nine osteoblasts was 1.78 μM, which demonstrates min-
imal toxicity in cells that lack constitutive activation of
STAT3. With respect to the concentrations of drug used in
these studies, preliminary pharmacokinetic data generated
in mice indicate that exposures above 1 μM occur
following intravenous and intraperitoenal administration of
LLL12 (J. Lin, data not shown). Doxorubicin administra-
tion to dogs results in peak plasma levels of drug ranging
from 1.3-1.5 μM, with drug concentrations above 0.2-0.4
μM lasting for 10–12 hours following a single IV bolus of
drug given over 20 minutes [42]. For the agents in combin-
ation, the IC50 of LLL12 is reduced from 0.23-0.4 μM to
0.08-0.11 μM which are concentrations that are achievable
in vivo; the IC50 of doxorubicin is reduced from 0.42-0.43
μM to 0.11-0.16 μM, which are also concentrations achiev-
able in vivo. Therefore, we believe the drug concentrations
used in this body of work are reflective of exposures ob-
tainable in vivo.
STAT3 transcriptional targets were all downregulated
after only 12 hours of 0.5 μM LLL12 treatment, showing
clear, rapid effects at biologically relevant concentrations.
Protein expression of pSTAT3 and survivin were simi-
larly downregulated under identical conditions. While
the timing of survivin downergulation lagged somewhat
behind the loss of pSTAT3, this was expected as STAT3
is a transcriptional activator of survivin and existing
transcript and protein would need to turn over first be-
fore a loss of survivin protein would be observed. Add-
itionally, normal canine osteoblasts which have little to
no pSTAT3 exhibit no loss of survivin protein at 12
hours of treatment, supporting the notion that STAT3
and not other transcription factors are linked to the loss
of survivin. Together, these results show that LLL12 is
more potent at inhibiting cell proliferation and decreas-
ing pSTAT3 protein expression than both LLL3 and
FLLL32.
The synergy experiments in combination with doxo-
rubicin show promise, with obvious clinical implications.
LLL12 has strong activity against cells with constitutive
pSTAT3 expression, but little effect on normal cells. The
significant dose reduction index seen when LLL12 isused with doxorubicin could permit its use in the setting
of lower doxorubicin doses, thereby potentially limiting
some of the acute and long-term toxicities associated
with dose intense doxorubicin. This has particular rele-
vance for dogs where cardiotoxicity limits the cumula-
tive dose of doxorubicin to 180 mg/m2 (typically 6
doses) and the pediatric population where cognitive defi-
ciencies, secondary neoplasia, and/or cardiac disease
occur as long-term consequences following dose-intense
treatment with doxorubicin.Conclusions
LLL12, a novel allosteric STAT3 inhibitor, inhibited
proliferation and promoted apoptosis in canine OS cell
lines. LLL12 decreased pSTAT3 and survivin expression
and downregulated the STAT3-mediated gene transcrip-
tion of survivin, cyclin D1, BCL-2 and MCL-1 within 12
hours of drug exposure in the nanomolar range. These
data support the clinical development of LLL12 for the
treatment of OS and other cancers in which STAT3 is
known to be constitutively activated.
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